白障明的诱变性试验研究  

STUDIES ON THE MUTAGENNICITY OF BENDAZAC LYSINE

作　　者：胡火珍[1] 邢一玲[1] 陶大昌[1] 郑雪莲[1] 杨正菀 范佳清[2] 靳洪武[2] 

机构地区：[1]华西医科大学基础医学院生物学与细胞生物学教研室,成都610041 [2]华西医科大学药学院药理学教研室

出　　处：《华西药学杂志》1990年第3期161-164,共4页West China Journal of Pharmaceutical Sciences

摘　　要：作者用鼠伤寒沙门氏菌回变试验,小鼠骨髓红细胞微核试验及CHL细胞染色体畸变试验,对白障明进行了诱变性试验研究。结果表明鼠伤寒沙门氏菌回变试验为阴性,该药可能不诱发基因突变,NIH小鼠骨髓红细胞微核试验及CHL细胞染色体畸变试验均为阴性,说明该药可能不诱发体内,体外染色体损伤作用。The mutagenicity of d- omestic Bendazac lysine was studied by Ames test micronucleus test of NIH mouse bone marrow and chromosome aberration assay in CHL cells. The results were as follow: The Ames test gave a negative result. It suggested that Bendazac lysine did not induced gene mutagenicity. The micironucleus test of NIH mouse bone marrow and chromosome aberration assay in CNL cells alse gave negative result, these results suggested that Bendazac lysine did not induced chromosome damage both in vitro in vivo.

关 键 词：白障明 诱变性试验 白内障 

分 类 号：R965.2[医药卫生—药理学]